Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis

References

• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009;11:376-82
   PubMed Web of Science ®Google Scholar
• Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008;24:121-7
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. Hypertension indication: drug labeling for cardiovascular outcome claims. Silver Spring, MD: U.S. Department of Health and Human Services FDA/Center for Drug Evaluation and Research 2011. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075072.pdf [Last accessed 13 January 2012]
   Google Scholar
• Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001;7:389-98
   PubMed Web of Science ®Google Scholar
• Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 2005;18:169-76S
   PubMed Web of Science ®Google Scholar
• Frishman WG. A historical perspective on the development of β-adrenergic blockers. J Clin Hypertens (Greenwich) 2007;9(4 Suppl 3):19-27
   PubMedGoogle Scholar
• Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009;54:1491-9
   PubMed Web of Science ®Google Scholar
• Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther 2003;28:179-86
   PubMed Web of Science ®Google Scholar
• Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag 2006;2:303-8
   PubMedGoogle Scholar
• Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-107
   PubMed Web of Science ®Google Scholar
• Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol 2009;53:379-87
   PubMed Web of Science ®Google Scholar
• Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8:35-44
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258-65
   PubMed Web of Science ®Google Scholar
• Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003;2:35-40
   PubMedGoogle Scholar
• Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998;12:135-40
   PubMed Web of Science ®Google Scholar
• Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 2011;33:1150-61
   PubMed Web of Science ®Google Scholar
• Stoschitzky K, Stoschitzky G, Brussee H, et al. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006;106:199-206
   PubMed Web of Science ®Google Scholar
• Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007;3:999-1005
   PubMedGoogle Scholar
• Gregoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002;55:728-35
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev 2005;12:27-35
   Google Scholar
• Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-5
   PubMed Web of Science ®Google Scholar
• Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45
   PubMed Web of Science ®Google Scholar
• Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009;40:213-20
   PubMed Web of Science ®Google Scholar
• Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239-45
   PubMed Web of Science ®Google Scholar
• Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich) 2008;10(1 Suppl 1):20-6
   PubMed Web of Science ®Google Scholar
• Arosio E, De Marchi S, Prior M, et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J Hypertens 2002;20:1793-7
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41
   PubMed Web of Science ®Google Scholar
• Ignarro LJ, Sisodia M, Trinh K, et al. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002;7:83-90
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25
   PubMed Web of Science ®Google Scholar
• Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care 2010;16:568-76
   PubMed Web of Science ®Google Scholar